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Introduction
■  Neratinib, an irreversible tyrosine kinase inhibitor of HER1, HER2 and HER4,1  
is used for the extended adjuvant treatment of early-stage HER2-positive 
(HER2+) breast cancer after trastuzumab-based adjuvant therapy.
‒  The primary analysis of the international, randomized, placebo-controlled 
phase III ExteNET trial showed that 1 year of neratinib given after trastuzumab-
based (neo)adjuvant therapy significantly improved 2-year invasive disease-free 
survival (iDFS) compared with placebo in women with early-stage HER2-
positive breast cancer (stratified hazard ratio [HR] 0.67; 95% confidence 
intervals [CI] 0.50–0.91; p=0.0091).2
‒  Furthermore, the significant iDFS benefits of neratinib were maintained after  
a median of 5 years’ follow-up (stratified hazard ratio 0.73; 95% CI 0.57‒0.92; 
p=0.008).3
■  Current knowledge about breast cancer is based largely on studies conducted in 
western populations.4 
–  As the genetic background, socio-economic profile, lifestyle, and health beliefs 
of Asian and western women differ, the findings from such studies may not be 
applicable to Asian women.4
‒  We report exploratory analyses from the ExteNET trial of patients enrolled 
from Asian centers to better understand the efficacy and safety of neratinib 
compared with placebo in Asian women with early-stage HER2-positive 
breast cancer.
Methods
Study overview
■  ExteNET is a multicenter, randomized, double-blind, parallel, placebo-controlled, 
phase III trial.
■  Patients were enrolled from centers in 40 countries in Europe, North and South 
America, Asia, and Australasia. 
■  The final study design comprised 3 parts: 
–  Part A: primary efficacy analysis at 2 years (July 2014)2
‒ Part B: sensitivity analysis of efficacy at 5 years (March 2017)3
‒ Part C: analysis of overall survival which is planned after 248 events. 
■  ExteNET is registered on Clinicaltrials.gov (identifier, NCT00878709).
Patients
■  Women with confirmed stage 2–3c (1–3c in original protocol) HER2-positive 
breast cancer.
■  Clinical and radiologic assessments were required to be negative for recurrences 
or metastatic disease at study entry.
■  Patients had received (neo)adjuvant therapy with trastuzumab completed within 
1 year (2 years in original protocol) before randomization.
Treatment
■  Women were randomly assigned to oral neratinib 240 mg once daily continuously 
or matching placebo for 1 year. 
■  Prophylaxis for the prevention of neratinib-associated diarrhea was not mandatory.
Assessments
■  During years 1 and 2, physical examinations were performed at month 1, every 
3 months during year 1, and every 4 months during year 2, mammograms were 
performed annually where appropriate, and computed tomography or bone 
scans were performed if clinically indicated. 
■  During years 3 to 5, physical examination and mammogram schedules were 
based on standard of care, and details of recurrent disease events and deaths 
were obtained from medical records.
Outcomes
■  The primary study endpoint was iDFS after 2 years of follow-up.
■  Secondary endpoints included disease-free survival including ductal carcinoma 
in situ (DCIS), time to distant recurrence, distant disease-free survival, cumulative 
incidence of central nervous system (CNS) recurrences, and safety.
Statistical analysis
■  Exploratory analyses were performed in the subpopulation of patients enrolled 
from Asian countries (i.e. China, Hong Kong, Japan, Korea, Malaysia, Singapore, 
and Taiwan).
■  Patients of Asian ethnicity enrolled from non-Asian countries (n=44) were not 
included in the Asian subpopulation. 
■  Efficacy analyses were by intention-to-treat and performed at 2 and 5 years 
post-randomization.
■  Kaplan Meier methods were used to analyze time-to-event endpoints, and a 
unstratified Cox proportional-hazards model was used to estimate HR with 95% 
CI for neratinib versus placebo.
Results
■  2840 women were randomly assigned to study treatment and constituted the 
intention to-treat population (neratinib, n=1420; placebo, n=1420).
■  341 women were enrolled from centers in Asia (neratinib, n=165; placebo, 
n=176) [Figure 1].
Figure 1. ExteNET analysis flowchart 
■  Patient demographics and characteristics at baseline were generally balanced 
between treatment groups in the Asian population (Table 1).
■  Compared with the intention-to-treat population, Asian patients (neratinib and 
placebo combined) were more likely to have node-negative disease (28.7% vs 
23.6%) and hormone receptor-negative tumors (52.2% vs 42.6%). 
■  Asian patients were also less likely to have received trastuzumab concurrently 
with chemotherapy (41.3% vs 62.3% in the intention-to-treat population),  
but more likely to have received an anthracycline plus taxane (81.2% vs 67.9%). 
Table 1. Baseline characteristics in Asian and intention-to-treat populations
Asian population
Intention-to-treat  
population
Variable
Neratinib
(n=165)
Placebo
(n=176)
Neratinib
(n=1420)
Placebo
(n=1420)
Age, years, median (range) 52 (26–81) 53 (27–72) 52 (25–83) 52 (23–82)
Body mass index, kg/m2 mean (SD) 22.6 (3.8) 23.1 (3.3) 27.4 (5.8) 27.5 (5.8)
Nodal status*
Negative 
1–3 positive node 
4+ positive nodes
43 (26.1) 
75 (45.5) 
47 (28.5)
55 (31.3) 
74 (42.0) 
47 (26.7)
335 (23.6) 
664 (46.8) 
421 (29.6)
336 (23.7) 
664 (46.8) 
420 (29.6)
Hormone receptor status*
Positive 
Negative
77 (46.7) 
88 (53.3)
86 (48.9) 
90 (51.1)
816 (57.5) 
604 (42.5)
815 (57.4) 
605 (42.6)
Previous trastuzumab regimen*
Concurrent 
Sequential
66 (40.0) 
99 (60.0)
75 (42.6) 
101 (57.4)
884 (62.3) 
536 (37.7)
886 (62.4) 
534 (37.6)
Menopausal status at diagnosis
Premenopausal 
Postmenopausal
90 (54.5) 
75 (45.5)
83 (47.2) 
93 (52.8)
663 (46.7) 
757 (53.3)
664 (46.8) 
756 (53.2)
Prior (neo)adjuvant therapy
Trastuzumab 
Anthracycline only 
Anthracycline plus taxane 
Taxane only 
Non-anthracycline or taxane
165 (100) 
17 (10.3) 
136 (82.4) 
12 (7.3) 
0
176 (100) 
21 (11.9) 
141 (80.1) 
13 (7.4) 
1 (0.6)
1420 (100) 
136 (9.6) 
962 (67.7) 
318 (22.4) 
4 (0.3)
1420 (100) 
135 (9.5) 
965 (68.0) 
316 (22.3) 
4 (0.3)
Data are presented as n (%), unless otherwise stated. SD, standard deviation. 
*Stratification factor.
Efficacy
■  Efficacy findings are summarized in Table 2 and Kaplan-Meier curves for iDFS 
are presented in Figure 2.
■  After 2 years’ follow-up, the iDFS rate in the Asian population was 92.8% in the 
neratinib group and 90.8% in the placebo group (HR 0.71; 95% CI 0.31–1.57), 
corresponding with an absolute between-group difference of 2.0%.
■  For other secondary endpoints, the trend favoring neratinib treatment was also 
consistently observed (Table 2). 
■  After 5 years’ follow-up, the iDFS rate in the Asian population was 91.9% in the 
neratinib group and 87.2% in the placebo group (HR 0.54; 95% CI 0.26–1.08), 
corresponding with an absolute between-group difference of 4.7%.
■  The number of CNS recurrences was numerically smaller in the neratinib group 
than in the placebo group at both time-points (1 vs 4 events, respectively).
Table 2. Efficacy findings after 2 and 5 years in the Asian and intention-to-treat 
populations
Parameter Asian population
Intention-to-treat  
population
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
P value
(2-sided)
Primary 2-year analysis
Invasive disease-free survival 
Disease-free survival with DCIS 
Distant disease-free survival 
Time to distant recurrences
0.70 (0.31–1.55) 
0.66 (0.29–1.43)  
0.59 (0.20–1.54) 
0.59 (0.20–1.54)
0.66 (0.49–0.90) 
0.61 (0.45–0.83) 
0.74 (0.52–1.05) 
0.73 (0.51–1.04)
0.008 
0.001 
0.094 
0.087
5-year analysis
Invasive disease-free survival 
Disease-free survival with DCIS 
Distant disease-free survival 
Time to distant recurrences
0.57 (0.27–1.13) 
0.55 (0.26–1.08) 
0.50 (0.21–1.07) 
0.50 (0.21–1.07)
0.73 (0.57–0.92) 
0.71 (0.56–0.89) 
0.78 (0.60–1.01) 
0.79 (0.60–1.03)
0.008 
0.004 
0.065 
0.078
CNS, central nervous system; CI, confidence intervals; DCIS, ductal carcinoma in situ.
Figure 2. iDFS in Asian and intention-to-treat populations at 2 years (A) and  
5 years (B) 
Treatment exposure
■  In the Asian population, the median duration of treatment was similar in both 
treatment arms (neratinib, 11.5 months; placebo, 11.6 months).
■  However, Asian patients were more likely to complete study treatment (neratinib, 
70.3%; placebo, 85.8%) than patients in the overall study population (62.1% vs 
82.9%, respectively).
Safety
■  In the Asian population, diarrhea was the most common adverse event with 
neratinib (Table 3); no grade 4 diarrhea occurred in either treatment group.
■  All other grade 3 events occurred in single patients only with neratinib.
■  Grade 4 events were reported in 1 patient (0.6%) in the neratinib group (anemia) 
and 3 patients (1.7%) in the placebo group (brain edema, n=1; amylase 
increased, abnormal hepatic function, cholestatic jaundice, n=1; gastric cancer, 
n=1). No grade 4 event was considered to be treatment related.
■  One grade 5 event (gastric cancer) occurred in the placebo group.
Table 3. Treatment-emergent adverse events in the Asian safety population 
(≥10% incidence)
Neratinib
(n=165)
Placebo
(n=176)
Adverse event, n (%) Any-grade Grade 3 Any-grade Grade 3
Diarrhea 
Nausea 
Fatigue 
Vomiting 
Abdominal pain 
Headache 
Abdominal pain upper 
Rash 
Decreased appetite 
Dizziness 
Stomatitis 
Nasopharyngitis 
Paronychia 
Influenza-like illness 
Weight decreased 
Pyrexia 
Palmar-plantar erythrodysesthesia
162 (98.2) 
58 (35.2) 
31 (18.8) 
51 (30.9) 
28 (17.0) 
27 (16.4) 
27 (16.4) 
51 (30.9) 
29 (17.6) 
15 (9.1) 
40 (24.4) 
25 (15.2) 
24 (14.5) 
23 (13.9) 
21 (12.7) 
17 (10.3) 
17 (10.3)
76 (46.1) 
1 (0.6) 
0 
1 (0.6) 
0 
0 
1 (0.6) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
0 
1 (0.6) 
0 
1 (0.6) 
0 
0
82 (46.6) 
30 (17.0) 
19 (10.8) 
14 (8.0) 
20 (11.4) 
27 (15.3) 
11 (6.3) 
17 (9.7) 
7 (4.0) 
21 (11.9) 
14 (8.0) 
54 (30.7) 
0 
22 (12.5) 
2 (1.1) 
10 (5.7) 
2 (1.1)
3 (1.7) 
0 
0 
0 
0 
0 
0 
0 
0 
1 (0.6) 
0 
0 
0 
0 
0 
0 
0
Note: Adverse events were graded according to National Cancer Institute Common Terminology 
Criteria, version 3.0.
■  With the exception of lower rates of dizziness and nasopharyngitis, Asian 
patients treated with neratinib experienced higher rates of all-grade adverse 
events compared with those who received placebo.
■  Grade 3 diarrhea was also more common with neratinib in Asian patients (46.1%) 
compared with the rate seen in the overall safety population (39.8%).
Conclusions
■  In ExteNET, the benefits of neratinib appeared to be similar among 
Asian patients than in the intention-to-treat population at both the 
2-year and 5-year timepoints.
■  Asian patients treated with neratinib experienced a higher rate 
of most adverse events compared with those receiving placebo, 
although this did not appear to impact on treatment duration or 
efficacy outcome. 
■  Despite small patient numbers, our analyses suggest that the 
findings from ExteNET are applicable to Asian patients.
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